BR9912327A - Inibidores da uroquinase - Google Patents

Inibidores da uroquinase

Info

Publication number
BR9912327A
BR9912327A BR9912327-4A BR9912327A BR9912327A BR 9912327 A BR9912327 A BR 9912327A BR 9912327 A BR9912327 A BR 9912327A BR 9912327 A BR9912327 A BR 9912327A
Authority
BR
Brazil
Prior art keywords
urokinase inhibitors
urokinase
inhibitors
amidino
metastasis
Prior art date
Application number
BR9912327-4A
Other languages
English (en)
Other versions
BR9912327B1 (pt
Inventor
Olaf Wilhelm
Viktor Magdolen
Joerg Stuerzebecher
John Foekens
Verena Lutz
Original Assignee
Wilex Biotechnology Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8232314&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9912327(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wilex Biotechnology Gmbh filed Critical Wilex Biotechnology Gmbh
Publication of BR9912327A publication Critical patent/BR9912327A/pt
Publication of BR9912327B1 publication Critical patent/BR9912327B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Patente de invenção para: <B>"INIBIDORES DA UROQUINASE"<D>. A invenção refere-se ao uso de derivados da 3-amidino-fenil-alanina como inibidores de uroquinase para o tratamento de tumores malignos e da formação de metástase.
BRPI9912327-4B1A 1998-07-20 1999-07-20 Inibidores da uroquinase BR9912327B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98113519 1998-07-20
PCT/EP1999/005145 WO2000004954A2 (de) 1998-07-20 1999-07-20 Neue urokinase-inhibitoren

Publications (2)

Publication Number Publication Date
BR9912327A true BR9912327A (pt) 2001-05-02
BR9912327B1 BR9912327B1 (pt) 2013-11-12

Family

ID=8232314

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9912327-4B1A BR9912327B1 (pt) 1998-07-20 1999-07-20 Inibidores da uroquinase

Country Status (12)

Country Link
US (2) US6624169B1 (pt)
EP (2) EP1098651B1 (pt)
JP (1) JP4603162B2 (pt)
AT (2) ATE230599T1 (pt)
AU (1) AU754958B2 (pt)
BR (1) BR9912327B1 (pt)
CA (1) CA2338073C (pt)
DE (2) DE59903981D1 (pt)
ES (2) ES2219607T3 (pt)
MX (1) MXPA01000553A (pt)
PT (1) PT1264828E (pt)
WO (1) WO2000004954A2 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9059798A (en) * 1998-09-18 2000-04-10 Pentapharm Ag Urokinase inhibitors
DE10013715A1 (de) 2000-03-20 2001-09-27 Wilex Biotechnology Gmbh Hochselektive Inhibitoren des Urokinase-Plasminogenaktivators
DE10029014A1 (de) * 2000-06-15 2001-12-20 Univ Schiller Jena Urokinase-Hemmstoffe
WO2002074756A2 (de) 2001-03-21 2002-09-26 Pentapharm Ag Urokinase-inhibitoren
US7838560B2 (en) * 2002-03-11 2010-11-23 The Medicines Company (Leipzig) Gmbh Urokinase inhibitors, production and use thereof
DE10225876A1 (de) * 2002-06-11 2003-12-24 Wilex Ag Guanidinophenylalaninverbindungen als Urokinase-Inhibitoren
DE10233632A1 (de) * 2002-07-24 2004-02-05 Wilex Ag Formulierungen von Phenylalanin-Derivaten
AU2003253326A1 (en) * 2002-07-25 2004-02-16 Wilex Ag Method for the production of phenylalanine derivatives
DE10238048A1 (de) * 2002-07-25 2004-02-05 Wilex Ag Verfahren zur Herstellung von Phenylalanin-Derivaten
DE10301300B4 (de) 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
DE10322191B4 (de) * 2003-05-16 2014-02-27 The Medicines Company (Leipzig) Gmbh N-sulfonylierte Aminosäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung
DE10323898A1 (de) 2003-05-26 2004-12-23 Wilex Ag Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe
DE10342108A1 (de) 2003-09-11 2005-04-14 Curacyte Chemistry Gmbh Basisch-substituierte Benzylaminanaloga als Inhibitoren des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung
EP1637529A1 (en) * 2004-09-20 2006-03-22 4Sc Ag Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of T-cell proliferation and uses thereof
DE102004045720A1 (de) * 2004-09-21 2006-03-23 Wilex Ag Stabile Dosierungsform von Phenylalanin-Derivaten
EP2087885A1 (en) 2005-06-24 2009-08-12 Wilex AG Use of urokinase inhibitors for the treatment and /or prevention of neuropathological diseases
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
CA2800684A1 (en) * 2010-05-26 2011-12-01 Expression Pathology, Inc. Urokinase-type plasminogen activator protein/plasminogen activator inhibitor type-1 protein selected reaction monitoring assay
WO2012004678A2 (en) 2010-07-07 2012-01-12 The Medicines Company (Leipzig) Gmbh Serine protease inhibitors
KR20210089265A (ko) 2015-03-30 2021-07-15 서니브룩 리서치 인스티튜트 암 치료 방법
KR101888249B1 (ko) * 2015-09-24 2018-08-13 주식회사 엘지화학 화합물 및 이를 포함하는 유기 전자 소자
AU2016336133B2 (en) * 2015-10-06 2021-02-25 Redhill Biopharma Ltd. Combination therapies for treating cancer
IL295658A (en) 2020-03-10 2022-10-01 Redhill Biopharma Ltd Treatment of coronavirus infection
US11471448B2 (en) 2020-12-15 2022-10-18 Redhill Biopharma Ltd. Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU541738B2 (en) 1979-09-20 1985-01-17 Nippon Chemiphar Co. Ltd. Cyclohexane carboxylic acid derivatives
DE3577700D1 (de) * 1984-11-30 1990-06-21 Shosuke Okamoto Lysinderivat und proteinase-inhibitor.
JPH05503300A (ja) * 1990-11-15 1993-06-03 ペンタファルム　アクチェンゲゼルシャフト メタ置換フェニルアラニン誘導体
CZ245994A3 (en) * 1993-02-10 1995-10-18 Pentapharm Ag Piperazides of substituted phenylalanine derivatives as thrombin inhibitors
US5550213A (en) * 1993-12-27 1996-08-27 Rutgers, The State University Of New Jersey Inhibitors of urokinase plasminogen activator
AU3107795A (en) * 1994-08-09 1996-03-07 Pentapharm Ag Inhibitors of the benzamidine type
DE9418185U1 (de) * 1994-11-12 1995-02-23 Richard Wolf Gmbh, 75438 Knittlingen Behälter für medizinische Instrumente
CH689611A5 (de) * 1995-03-01 1999-07-15 Pentapharm Ag Urokinase-Inhibitoren.
AU9059798A (en) 1998-09-18 2000-04-10 Pentapharm Ag Urokinase inhibitors

Also Published As

Publication number Publication date
ATE264103T1 (de) 2004-04-15
ATE230599T1 (de) 2003-01-15
BR9912327B1 (pt) 2013-11-12
DE59909210D1 (de) 2004-05-19
US6624169B1 (en) 2003-09-23
JP4603162B2 (ja) 2010-12-22
US20030013723A1 (en) 2003-01-16
WO2000004954A2 (de) 2000-02-03
EP1264828A1 (de) 2002-12-11
US6680320B2 (en) 2004-01-20
MXPA01000553A (es) 2002-04-24
WO2000004954A3 (de) 2000-06-22
CA2338073C (en) 2010-09-21
JP2002521348A (ja) 2002-07-16
EP1098651B1 (de) 2003-01-08
AU754958B2 (en) 2002-11-28
AU5161599A (en) 2000-02-14
PT1264828E (pt) 2004-08-31
EP1098651A2 (de) 2001-05-16
EP1264828B1 (de) 2004-04-14
ES2189455T3 (es) 2003-07-01
DE59903981D1 (de) 2003-02-13
ES2219607T3 (es) 2004-12-01
CA2338073A1 (en) 2000-02-03

Similar Documents

Publication Publication Date Title
BG105369A (en) Arylpiperazines and their use as metalloproteinase inhibiting agent (mmp
PT1413582E (pt) Pirrolobenzodiazepinas dimericas
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
AR023777A1 (es) Nuevos compuestos
PT1140944E (pt) Derivados de epotilona e sua utilizacao como agentes antitumorais
BR9805544C1 (pt) Uso de um composto.
ES2184149T3 (es) Paclitaxeles 6-tio sustituidos.
WO2000004954A3 (de) Neue urokinase-inhibitoren
ATE335814T1 (de) Modifizierte arginindeaminase
DK1104425T3 (da) Hidtil ukendte thiazolopyrimidinforbindelser
BR0113798A (pt) Derivados de resorcinol
BR9711586A (pt) Compostos e uso dos mesmo
ATE239509T1 (de) Konjugate zur behandlung von prostatakrebs
DE60121461D1 (de) Kondensierte pyridoindolderivate
BR9913533A (pt) Processos para tratar hipertensão e composições para uso nos mesmos
BRPI0110506B8 (pt) uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose
AU8004301A (en) Derivatives of branched-chain lipophilic molecules and uses thereof
EA200200545A1 (ru) Онколитические комбинации для лечения рака
BR0012675A (pt) Uso de inibidores de il-18
SE9801494D0 (sv) Novel use
AU2001266838A1 (en) Inhibitors of matriptase for the treatment of cancer
SE0003476D0 (sv) Compounds
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos
BR0110902A (pt) Inibidores de mmp-9/mmp-2

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25G Requested change of headquarter approved

Owner name: WILEX AG (DE)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020080117818/RJ DE 08/09/2008.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13 E 25 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2013, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE AO DESPACHO 16.1 PUBLICADO NA RPI 2236 DE 12.11.2013, QUANTO AO NOME E ENDERECO DO TITULAR

B15K Others concerning applications: alteration of classification

Ipc: A61K 31/495 (2006.01), A61K 51/04 (2006.0

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2523 DE 14-05-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.